Zobrazeno 1 - 7
of 7
pro vyhledávání: '"Pieter L. Lindenbergh"'
Autor:
Sjoukje J. C. van der Stegen, Pieter L. Lindenbergh, Roseanna M. Petrovic, Hongyao Xie, Mame P. Diop, Vera Alexeeva, Yuzhe Shi, Jorge Mansilla-Soto, Mohamad Hamieh, Justin Eyquem, Annalisa Cabriolu, Xiuyan Wang, Ramzey Abujarour, Tom Lee, Raedun Clarke, Bahram Valamehr, Maria Themeli, Isabelle Riviere, Michel Sadelain
Publikováno v:
van der Stegen, S J C, Lindenbergh, P L, Petrovic, R M, Xie, H, Diop, M P, Alexeeva, V, Shi, Y, Mansilla-Soto, J, Hamieh, M, Eyquem, J, Cabriolu, A, Wang, X, Abujarour, R, Lee, T, Clarke, R, Valamehr, B, Themeli, M, Riviere, I & Sadelain, M 2022, ' Generation of T-cell-receptor-negative CD8αβ-positive CAR T cells from T-cell-derived induced pluripotent stem cells ', Nature Biomedical Engineering, vol. 6, no. 11, pp. 1284-1297 . https://doi.org/10.1038/s41551-022-00915-0
Nature Biomedical Engineering, 6(11), 1284-1297. Nature Publishing Group
Nat Biomed Eng
Nature Biomedical Engineering, 6(11), 1284-1297. Nature Publishing Group
Nat Biomed Eng
The production of autologous T cells expressing a chimaeric antigen receptor (CAR) is time-consuming, costly and occasionally unsuccessful. T-cell-derived induced pluripotent stem cells (TiPS) are a promising source for the generation of ‘off-the-s
Autor:
Matthew J. Meyer, Emma Lees, Heather Huet, Tuna Mutis, Niels W.C.J. van de Donk, Pieter L. Lindenbergh, Juliet A. Williams, Isabelle Isnardi, Thomas Calzascia, Jennifer Johnson, Rebecca Ward, Eugene Choi, Johanna Koelln, Meike Scharenberg, Xavier Charles Leber, Nicole Balke, Christina Dornelas, Yeonju Shim, Sinan Isim, Fangmin Xu, Meghan Flaherty, Stefan Ewert, Babette Wolf, Sunyoung Jang, Dongshu Chen, Ryan D. Molony, Haihui Lu
Supplementary Figures S1-S9 show CD32b mRNA vs protein expression, preclinical activity of NVS32b1 vs NVS32b2, differential activation of human vs mouse FcgRs, CD32b expression on cell lines and healthy immune cells.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b1e6e0551ab4919478079f86794a8378
https://doi.org/10.1158/1535-7163.22507092.v1
https://doi.org/10.1158/1535-7163.22507092.v1
Autor:
Matthew J. Meyer, Emma Lees, Heather Huet, Tuna Mutis, Niels W.C.J. van de Donk, Pieter L. Lindenbergh, Juliet A. Williams, Isabelle Isnardi, Thomas Calzascia, Jennifer Johnson, Rebecca Ward, Eugene Choi, Johanna Koelln, Meike Scharenberg, Xavier Charles Leber, Nicole Balke, Christina Dornelas, Yeonju Shim, Sinan Isim, Fangmin Xu, Meghan Flaherty, Stefan Ewert, Babette Wolf, Sunyoung Jang, Dongshu Chen, Ryan D. Molony, Haihui Lu
Supplementary Materials and Methods, Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8d51c542291783435ac716a325492042
https://doi.org/10.1158/1535-7163.22507095
https://doi.org/10.1158/1535-7163.22507095
Autor:
Sjoukje J.C. van der Stegen, Roseanna M. Petrovic, Pieter L. Lindenbergh, Mame P. Diop, Vera Alexeeva, Hongyao Xie, Raedun Clarke, Bahram Valamehr, Isabelle Rivière, Michel Sadelain
Publikováno v:
Blood. 140:10290-10291
Autor:
Yeonju Shim, Babette Wolf, Sinan Isim, Christina Dornelas, Isabelle Isnardi, Fangmin Xu, Sunyoung Jang, Heather Huet, Juliet Williams, Matthew J. Meyer, Pieter L. Lindenbergh, Emma Lees, Niels W.C.J. van de Donk, Stefan Ewert, Thomas Calzascia, Haihui Lu, Dongshu Chen, Meike Scharenberg, Jennifer Johnson, Rebecca Ward, Ryan D. Molony, Johanna Koelln, Eugene Choi, Nicole Balke, Tuna Mutis, Meghan Flaherty, Xavier Charles Leber
Publikováno v:
Lu, H, Molony, R D, Chen, D, Jang, S, Wolf, B, Ewert, S, Flaherty, M, Xu, F, Isim, S, Shim, Y, Dornelas, C, Balke, N, Leber, X C, Scharenberg, M, Koelln, J, Choi, E, Ward, R, Johnson, J, Calzascia, T, Isnardi, I, Williams, J A, Lindenbergh, P L, van de Donk, N W C J, Mutis, T, Huet, H, Lees, E & Meyer, M J 2020, ' Development of anti-CD32b antibodies with enhanced Fc function for the treatment of B and plasma cell malignancies ', Molecular Cancer Therapeutics, vol. 19, no. 10, pp. 2089-2104 . https://doi.org/10.1158/1535-7163.MCT-19-0003
Molecular Cancer Therapeutics, 19(10), 2089-2104. American Association for Cancer Research Inc.
Molecular Cancer Therapeutics, 19(10), 2089-2104. American Association for Cancer Research Inc.
The sole inhibitory Fcγ receptor CD32b (FcγRIIb) is expressed throughout B and plasma cell development and on their malignant counterparts. CD32b expression on malignant B cells is known to provide a mechanism of resistance to rituximab that can be
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::61025397e55e42dec57f510fa1afc300
https://research.vumc.nl/en/publications/842430e7-1780-4537-9e71-f3baefef0813
https://research.vumc.nl/en/publications/842430e7-1780-4537-9e71-f3baefef0813
Autor:
Jorge Mansilla-Soto, Justin Eyquem, Sascha Haubner, Mohamad Hamieh, Judith Feucht, Noémie Paillon, Andrés Ernesto Zucchetti, Zhuoning Li, Maria Sjöstrand, Pieter L. Lindenbergh, Michelle Saetersmoen, Anton Dobrin, Mathieu Maurin, Archana Iyer, Andreina Garcia Angus, Matthew M. Miele, Zeguo Zhao, Theodoros Giavridis, Sjoukje J. C. van der Stegen, Fella Tamzalit, Isabelle Rivière, Morgan Huse, Ronald C. Hendrickson, Claire Hivroz, Michel Sadelain
Publikováno v:
Nat Med
Chimeric antigen receptors (CARs) are receptors for antigen that direct potent immune responses. Tumor escape associated with low target antigen expression is emerging as one potential limitation of their efficacy. Here we edit the TRAC locus in huma
Autor:
Noemi Anna Nagy, Pieter L Lindenbergh, Maria Themeli, Sonja Zweegman, Henk M. Lokhorst, Richard W.J. Groen, Patty Bosman, Jhon Marin Soto, Louise Nieuwenhuis, Tuna Mutis, Inger S. Nijhof, Niels W.C.J. van de Donk, Claudia Stege, Kristine A Frerichs, Marloes E.C. Broekmans
Publikováno v:
Expert Review of Clinical Immunology, 14(3), 197-206. Taylor and Francis Ltd.
Frerichs, K A, Nagy, N A, Lindenbergh, P L, Bosman, P, Marin Soto, J, Broekmans, M, Groen, R W J, Themeli, M, Nieuwenhuis, L, Stege, C, Nijhof, I S, Mutis, T, Zweegman, S, Lokhorst, H M & van de Donk, N W C J 2018, ' CD38-targeting antibodies in multiple myeloma : mechanisms of action and clinical experience ', Expert Review of Clinical Immunology, vol. 14, no. 3, pp. 197-206 . https://doi.org/10.1080/1744666X.2018.1443809
Frerichs, K A, Nagy, N A, Lindenbergh, P L, Bosman, P, Marin Soto, J, Broekmans, M, Groen, R W J, Themeli, M, Nieuwenhuis, L, Stege, C, Nijhof, I S, Mutis, T, Zweegman, S, Lokhorst, H M & van de Donk, N W C J 2018, ' CD38-targeting antibodies in multiple myeloma : mechanisms of action and clinical experience ', Expert Review of Clinical Immunology, vol. 14, no. 3, pp. 197-206 . https://doi.org/10.1080/1744666X.2018.1443809
INTRODUCTION: Multiple myeloma (MM) is generally an incurable hematological malignancy with heterogeneous overall survival rates ranging from a few months to more than 10 years. Survival is especially poor for patients who developed disease that is r